Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular changes in gliomas.

Marc Sanson1, Joëlle Thillet, Khê Hoang-Xuan

  • 1INSERM U495, Laboratoire de Biologie des Interactions Neurones-Glie, Paris, France. m.sanson@psl.ap-hop-paris.fr

Current Opinion in Oncology
|January 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiological and FDG-PET imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas.

Journal of neurology·2026
Same author

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

CAR T-Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study.

American journal of hematology·2026
Same author

Prognostic factors in adult patients with medulloblastoma.

Neuro-oncology practice·2026
Same author

18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Consolidation radiotherapy for primary CNS lymphoma: The lower, the better.

Neuro-oncology·2025

Recent advances in glioma molecular biology offer hope for improved classification and targeted therapies. Understanding genetic alterations and lineage markers is key to developing better diagnostic and prognostic tools for these brain tumors.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Genetics

Background:

  • Gliomas have a poor prognosis despite optimal treatment, with limited recent therapeutic progress.
  • Significant advancements in understanding glioma oncogenesis have been made.
  • This review synthesizes recent molecular biology findings in glial tumors.

Purpose of the Study:

  • To review recent advances in the molecular biology of glial tumors.
  • To emphasize lineage markers, genetic mechanisms of tumor progression, and novel diagnostic/prognostic markers.
  • To identify potential therapeutic targets for glioma treatment.

Main Methods:

  • Review of current literature on glioma molecular genetics and pathogenesis.
  • Analysis of genotype/phenotype correlations and their impact on classification.

Related Experiment Videos

  • Examination of studies on lineage markers, genetic alterations, and cellular pathway disruptions.

    • Main Results:

    • The cell of origin for gliomas remains under investigation, with evidence supporting multipotent progenitors.
    • Genetic alterations affecting RB1, P53, and tyrosine kinase receptor pathways are common in gliomas.
    • Specific genetic markers, such as 1p/19q deletion in oligodendrogliomas, provide prognostic value and complement existing classifications.

    Conclusions:

    • Advances in molecular genetics significantly benefit glioma management, particularly oligodendrogliomas with 1p/19q deletion.
    • Improved understanding of molecular pathogenesis and cellular lineage will refine tumor classification and prognostic markers.
    • This knowledge holds promise for identifying novel therapeutic strategies against gliomas.